2012-12-03 16:16:00 -

A number of stocks were upgraded and downgraded by equities research analysts
today, as reported by Analyst Ratings Network ( bit.ly/equitybriefdaily)
and Equity Brief:

CRT Capital downgraded shares of Health Management Associates (HMA) from a fair
value rating to a sell rating. Their analysts now have a $6.50 price target on
the stock.

Deutsche Bank upgraded shares of International Game Technology (IGT) from a hold
rating to a buy rating. Deutsche Bank now has a $19.00 price target on the
stock, up previously from $16.00.

Sterne Agee lowered its price target on shares of Intel (INTC) from $19.00 to
$18.00. They have a neutral rating on the stock.

Credit Suisse upgraded shares of Itau Unibanco Holding Sociedade Anonima (ITUB)
from an underperform rating to a neutral rating.

Goldman Sachs downgraded shares of Janus   Capital Group Inc. (JNS) from a neutral
rating to a sell rating. Their analysts now have a $7.00 price target on the
stock, down previously from $8.00. They wrote, "We expect JNS shares to
underperform given: (1) Soft relative equity fund performance and tougher INTECH
performance comparisons suggest more outflows; (2) pressure on revenues and op.
margin from negative performance fees; and (3) we see multiple compression as
investors refocus on soft fundamentals as technical tailwind from Dai-ichi's
purchase of a 20% stake rolls off. We lower our 2012/2013/2014 EPS estimates to
$0.56/$0.53/$0.60 from $0.56/$0.60/$0.71 on modest flow/margin expectations,
9-15% below consensus."

JMP Securities downgraded shares of Kenexa Co. (KNXA) from an outperform rating
to a market perform rating.

Canaccord Genuity initiated coverage on shares of Lululemon (LULU). They issued
a buy rating on the stock and set a $91.00 price target. They wrote, "We are
initiating coverage of LULU with a BUY rating and $91 price target. We believe
LULU is evolving from an athletic brand with its roots in yoga to a lifestyle
brand that is marrying form and function. To that end, the company has had
issues in keeping pace with demand. Our supply chain checks suggest capacity in
2013 will expand and as a result traffic and conversion should improve,
resulting in a reacceleration of comp growth."

Mizuho downgraded shares of Myriad Genetics (MYGN) from a buy rating to a
neutral rating. Their analysts now have a $30.00 price target on the stock, down
previously from $31.00.

Goldman Sachs downgraded shares of Myriad Genetics (MYGN) from a buy rating to a
neutral rating.

Barclays Capital upgraded shares of Nisource (NI) from an equal weight rating to
an overweight rating. Barclays Capital now has a $27.00 price target on the
stock, up previously from $26.00.

Stay on top of analysts' coverage with Analyst Ratings Network's free daily
email newsletter that provides a concise list of analysts' upgrades, downgrades
and initiations. Register at  bit.ly/equitybriefdaily

Content and Media Contact: newseditor@equitybrief.net




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Equity Brief via Thomson Reuters ONE
[HUG#1662116]